D-0060-2023 Class II Terminated
FDA drug recall D-0060-2023 was initiated by ImprimisRx NJ on Nov 9, 2022 and is designated Class II. Reason for recall: Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost. The recall status is terminated (terminated Aug 23, 2023). Affected quantity: 960 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 23, 2022
- Initiation Date
- Nov 9, 2022
- Termination Date
- Aug 23, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 960 bottles
Product description
Timolol-Latanoprost (0.5/0.005%) ophthalmic drops, Compounded, 5 mL bottle, Imprimis Rx, Ledgewood, NJ.
Reason for recall
Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.
Distribution pattern
Nationwide in the USA
Code information
Lot # 06272022@3, Exp. date 11/24/2022 Lot # 08302022@1, Exp. date 01/27/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0060-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026